Trial Profile
A Phase 2b/3 Study to Evaluate the Safety, Tolerability, and Effects of Livoletide (AZP-531), an Unacylated Ghrelin Analogue, on Food-related Behaviors in Patients With Prader-Willi Syndrome
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Livoletide (Primary)
- Indications Prader-Willi syndrome
- Focus Registrational; Therapeutic Use
- Acronyms ZEPHYR
- Sponsors Millendo Therapeutics SAS
- 18 Dec 2021 Trial has been completed in Italy (End date :2020-05-25)
- 18 Apr 2020 Trial has been completed in Belgium (End date :2020-04-06)
- 06 Apr 2020 According to a Millendo Therapeutics media release, due to disappointing results, the company is discontinuing the livoletide program(including the extension study) in PWS and focus on development of pipeline assets nevanimibe and MLE-301.